Filing Details

Accession Number:
0000950170-25-030289
Form Type:
13G Filing
Publication Date:
2025-02-27 19:00:00
Filed By:
Adjuvant Global Health Technology Fund, L.P.
Company:
An2 Therapeutics Inc.
Filing Date:
2025-02-28
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Adjuvant Global Health Technology Fund, L.P. 0 1,995,958 6.7%
Adjuvant Global Health Technology Fund DE, L.P. 0 377,542 1.3%
Adjuvant Capital GP, L.P. 0 2,373,500 7.9%
Adjuvant Capital Management, L.L.C. 0 2,373,500 7.9%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
Adjuvant Global Health Technology Fund, L.P.
 
Signature:/s/ Kabeer Aziz
Name/Title:Vice President and Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of Adjuvant Capital GP, L.P.
Date:02/28/2025
 
Adjuvant Global Health Technology Fund DE, L.P.
 
Signature:/s/ Kabeer Aziz
Name/Title:Vice President and Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of Adjuvant Capital GP, L.P.
Date:02/28/2025
 
Adjuvant Capital GP, L.P.
 
Signature:/s/ Kabeer Aziz
Name/Title:Vice President and Secretary of Adjuvant Capital Management, L.L.C., the sole general partner of Adjuvant Capital GP, L.P.
Date:02/28/2025
 
Adjuvant Capital Management, L.L.C.
 
Signature:/s/ Kabeer Aziz
Name/Title:Vice President and Secretary
Date:02/28/2025